Trial Profile
A Phase II Open Label Study of the Safety, Pharmacokinetics, and Efficacy of a True Human Anti-inflammatory Therapeutic Antibody (RA-18C3) in Subjects With Moderate to Severe Plaque Psoriasis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bermekimab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 04 Mar 2015 According to a XBiotech media release, results from this study have been published in the JAMA Dermatology.
- 04 Mar 2015 Results published in a XBiotech media release.
- 17 Oct 2012 Preliminary results have been reported in a XBiotech media release. Full results will be submitted to a peer-reviewed journal for future publication.